GlaxoSmithKline
OverviewSuggest Edit
| Type | Public | |
| Founded | 2000 | |
| HQ | Brentford, GB | Map |
| Website | gsk.com | |
| Employee Ratings | More |
Recent NewsAll News
- FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
- GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
- GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer
- GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Key People/Management at GlaxoSmithKline
Jonathan Symonds
Emma Walmsley
Dmytro Oliinyk
Simon Dingemans
Shakir Rahim
Iain MacKay
GlaxoSmithKline Office Locations
GlaxoSmithKline Financials and Metrics
GlaxoSmithKline Revenue
| GBP | |
|---|---|
Revenue (Q2, 2019) | 7.8b |
Gross profit (Q2, 2019) | 5.2b |
Gross profit margin (Q2, 2019), % | 66.2% |
Net income (Q2, 2019) | 1.1b |
EBIT (Q2, 2019) | 1.5b |
Market capitalization (29-May-2020) | 83.9b |
Closing stock price (29-May-2020) | 1.7k |
Cash (30-Jun-2019) | 4.1b |
EV | 113.2b |
| GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|
Net Income | 1.2b | 1.1b | 2.5b | 759.0m | 1.2b | 1.5b | 985.0m | 2.0b |
Depreciation and Amortization | 326.0m | 1.4b | 2.1b | 478.0m | 673.0m | 1.2b | 1.2b | 2.0b |
Cash From Operating Activities | 1.1b | 2.2b | 4.0b | 863.0m | 2.2b | 4.3b | 663.0m | 2.1b |
Purchases of PP&E | (260.0m) | (639.0m) | (1.0b) | (258.0m) | (541.0m) | (842.0m) | (222.0m) | (501.0m) |
| GBP | Y, 2019 |
|---|---|
EV/EBIT | 76.3 x |
EV/CFO | 55.2 x |
EV/FCF | 70.1 x |
Debt/Equity | 11.3 x |
Debt/Assets | 0.5 x |
Financial Leverage | 21.4 x |
GlaxoSmithKline Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| TESARO | December 04, 2018 | $5.10 b |
| Novartis | March 27, 2018 | $13 b |
| GlycoVaxyn | February 11, 2015 | $190 m |
| Okairos AG | May 29, 2013 | $325 m |
| Human Genome Sciences | August 03, 2012 | $3 b |
| CellZome | May 15, 2012 | £61 m |
| MaxiNutrition | December 13, 2010 | £162 m |
| Nanjing MeiRui Pharma Co., Ltd. | December 07, 2010 | $70 m |
| Laboratorios Phoenix | June 09, 2010 | $253 m |
| NovaMin Technology | May 24, 2010 | $135 m |
GlaxoSmithKline Revenue Breakdown
GlaxoSmithKline revenue breakdown by business segment: 24.8% from Consumer Healthcare, 19.1% from Vaccines and 56.0% from Global Pharmaceuticals
GlaxoSmithKline revenue breakdown by geographic segment: 25.9% from Europe, 35.3% from International and 38.9% from US
Human Capital Metrics
GlaxoSmithKline Online and Social Media Presence
197.89k Twitter followers
GlaxoSmithKline has 197.89k Twitter Followers. The number of followers has increased 1.8% month over month and increased 4.9% quarter over quarter
GlaxoSmithKline's Trends
Twitter Engagement Stats for @gsk
11.6k
Tweets
703
Following
197.9k
Followers
81
Tweets last 30 days
24.2
Avg. likes per Tweet
82.7%
Tweets with engagement
GlaxoSmithKline Blogs
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
GSK completes divestment of Horlicks and other Consumer Healthcare nutrition products in India and certain other markets
GlaxoSmithKline Frequently Asked Questions
When was GlaxoSmithKline founded?
GlaxoSmithKline was founded in 2000.
Who are GlaxoSmithKline key executives?
GlaxoSmithKline's key executives are Jonathan Symonds, Emma Walmsley and Dmytro Oliinyk.
How many employees does GlaxoSmithKline have?
GlaxoSmithKline has 95,490 employees.
What is GlaxoSmithKline revenue?
Latest GlaxoSmithKline annual revenue is £30.8 b.
What is GlaxoSmithKline revenue per employee?
Latest GlaxoSmithKline revenue per employee is £322.8 k.
Who are GlaxoSmithKline competitors?
Competitors of GlaxoSmithKline include Bayer, Novartis and Merck.
Where is GlaxoSmithKline headquarters?
GlaxoSmithKline headquarters is located at 980 Great West Rd, Brentford.
Where are GlaxoSmithKline offices?
GlaxoSmithKline has offices in Brentford, Tiranë, Boudouaou, Victoria and in 70 other locations.
How many offices does GlaxoSmithKline have?
GlaxoSmithKline has 88 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies